CD19 and precursor B-cell acute lymphoblastic leukemia: CD19-targeting chimeric antigen receptor-engineered T cells (CAR-T) represent a major advancement in refractory/relapsed (R/R) B-cell acute lymphocytic leukemia (B-ALL) with high initial complete remission (CR) rate of around 70–90% [1–8].